PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30860683-1	2019	OBJECTIVES: Vandetanib  lenvatinib, and cabozantinib are tyrosine kinase inhibitors (TKIs) targeting VEGFR subtypes 1 and 2, EGFR and the RET-tyrosine kinase, thus considered as multiple TKIs.	vandetanib	12-22	epidermal growth factor receptor	Homo sapiens	102-106